What to Do About Primary-Prevention Implantable Cardiac Defibrillators in Patients with Improved Ejection Fraction
Tóm tắt
Approximately 20–40 % of heart failure patients with reduced ejection fraction (EF) demonstrate substantial improvements in their EF during follow-up. A subset of these patients who had originally received implantable cardioverter defibrillators (ICD) for the primary prevention of sudden cardiac death (i.e., patients with EF < 35 %) pose a challenge to cardiologists when they present with improvements in EF to above 35 % at the time of their battery depletion. Little is known about the risk of sudden cardiac death in these patients. Is the risk high enough to warrant the replacement of the ICD generator? In the following article, we review the available data on the risk of sudden cardiac death in these patients, and aim to assist the clinician and the patient in making informed decisions about whether the ICD therapy should be continued.
Tài liệu tham khảo
Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. NEJM. 2005;352(3):225–37.
Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. NEJM. 2002;346(12):877–83.
Punnoose LR, Givertz MM, Lewis EF, Pratibhu P, Stevenson LW, Desai AS. Heart failure with recovered ejection fraction: a distinct clinical entity. J Card Fail. 2011;17(7):527–32. This is the first paper introducing the concept of heart failure with recovered ejection fraction in the literature.
Linton NW. Arrhythmia and left ventricular ejection fraction: once broken, always broken? Heart Rhythm. 2013;10(6):847–8.
Adabag AS, Luepker RV, Roger VL, Gersh BJ. Sudden cardiac death: epidemiology and risk factors. Nat Rev Cardiol. 2010;7(4):216–25.
Chugh SS, Reinier K, Teodorescu C, Evanado A, Kehr E, Al Samara M, et al. Epidemiology of sudden cardiac death: clinical and research implications. Prog Cardiovasc Dis. 2008;51(3):213–28.
Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. NEJM. 2004 May 20;350(21):2151–8.
Narayanan K, Reinier K, Uy-Evanado A, Teodorescu C, Chugh H, Marijon E, et al. Frequency and determinants of implantable cardioverter defibrillator deployment among primary prevention candidates with subsequent sudden cardiac arrest in the community. Circulation. 2013;128(16):1733–8.
Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. NEJM. 2001;345(20):1473–82.
Adabag S, Smith LG, Anand IS, Berger AK, Luepker RV. Sudden cardiac death in heart failure patients with preserved ejection fraction. J Card Fail. 2012;18(10):749–54.
Campbell RT, Jhund PS, Castagno D, Hawkins NM, Petrie MC, McMurray JJ. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? J Am Coll Cardiol. 2012;60(23):2349–56.
Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation. 2010;121(12):1393–405.
Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJ, et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2004;110(15):2180–3.
Steimle AE, Stevenson LW, Fonarow GC, Hamilton MA, Moriguchi JD. Prediction of improvement in recent onset cardiomyopathy after referral for heart transplantation. J Am Coll Cardiol. 1994;23(3):553–9.
McNamara DM, Starling RC, Cooper LT, Boehmer JP, Mather PJ, Janosko KM, et al. Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study. J Am Coll Cardiol. 2011;58(11):1112–8.
Schliamser JE, Kadish AH, Subacius H, Shalaby A, Schaechter A, Levine J, et al. Significance of follow-up left ventricular ejection fraction measurements in the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation trial (DEFINITE). Heart Rhythm. 2013;10(6):838–46.
Naksuk N, Saab A, Li JM, Florea V, Akkaya M, Anand IS, et al. Incidence of appropriate shock in implantable cardioverter-defibrillator patients with improved ejection fraction. J Card Fail. 2013;19(6):426–30.
Manfredi JA, Al-Khatib SM, Shaw LK, Thomas L, Fogel RI, Padanilam B, et al. Association between left ventricular ejection fraction post-cardiac resynchronization treatment and subsequent implantable cardioverter defibrillator therapy for sustained ventricular tachyarrhythmias. Circ Arrhythm Electrophysiol. 2013;6(2):257–64.
Nerheim P, Birger-Botkin S, Piracha L, Olshansky B. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation. 2004;110(3):247–52.
Barra S, Agarwal S. Should an improvement in left ventricular systolic function preclude ICD generator replacement? Heart Rhythm. 2013;10(9):e76–7.
Chad M House DN, William B Nelson, Dennis W Zhu. Normalization of Left Ventricular Ejection Fraction is Associated With the Absence of Appropriate Anti-Tachycardia Therapy in Patients Receiving Implantable Defibrillators for the Primary Prevention of Sudden Death Circulation. 2013;128 (Supl) (abst 15027).
Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, et al. Reduction in inappropriate therapy and mortality through ICD programming. NEJM. 2012;367(24):2275–83.